Compare KSCP & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSCP | ENTX |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 62.6M |
| IPO Year | 2022 | 2015 |
| Metric | KSCP | ENTX |
|---|---|---|
| Price | $2.95 | $1.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $17.00 | $9.00 |
| AVG Volume (30 Days) | ★ 470.2K | 96.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.54 | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $11,335,000.00 | $42,000.00 |
| Revenue This Year | $218.66 | N/A |
| Revenue Next Year | $54.32 | N/A |
| P/E Ratio | ★ N/A | $17.43 |
| Revenue Growth | ★ 4.91 | N/A |
| 52 Week Low | $2.52 | $0.91 |
| 52 Week High | $10.13 | $3.22 |
| Indicator | KSCP | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 54.59 |
| Support Level | $2.52 | $1.17 |
| Resistance Level | $4.50 | $1.37 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 62.01 | 65.00 |
Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.